Navigation Links
Silencer Validated siRNAs

les for siRNA Design
On average, 50% of the siRNAs featuring the Tuschl design rules (3' UU overhangs, <50% G/C content; 2-4) provide at least 50% reduction in target gene expression. An early goal for Cenix was to improve the percentage of effective siRNAs by improving the design rules for siRNAs. To accomplish this, Cenix tested several hundred siRNAs targeting a number of endogenous human gene products that were expressed at detectable levels in several different cell lines. The effective and ineffective siRNAs were used to judge the impact of a number of physical characteristics on siRNA activity, including Tm, predicted RNA secondary structure, nucleotide position effects, nucleotide content of the 3' overhangs, siRNA length, and nucleotide distribution over the length of the siRNA. Those characteristics that correlated with siRNA effectiveness were incorporated into a design algorithm. The final step of designing the algorithm was a BLAST search to ensure that the siRNA was specific to the gene of interest.

The algorithm was then tested for its capacity to identify effective siRNAs. siRNAs targeting 60 human genes were designed, prepared, and tested across as many as four cell lines. Of the genes whose expression could be reduced without causing cell death, 89% of the designed siRNAs provided greater than 70% reduction in target gene expression (Figure 1).

The design algorithm is now being tested on hundreds of human genes. The first siRNA sequences validated during this collaborative study are being made available by Ambion and Cenix BioScience as part of the Silencer Validated siRNA product line. As the study progresses, many more additional sequences will be added to this line. '"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA
2. Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
3. Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function
4. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
5. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
6. Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit
7. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
8. Using Validated siRNAs in Functional Genomic Assays
9. Cenix-Designed siRNAs for 95% of Human and Mouse Genomes
10. Five Ways to Produce siRNAs
11. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Silencer Validated siRNAs

(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -- STOCKHOLM, August 27, 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Massachusetts, August 26, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... CARY, N.C., Aug. 26 SciQuest, Inc ... procurement and supplier enablement solutions, ... list of the fastest-growing, private companies in America. ... in 2007. (Logo: http://photos.prnewswire.com/prnh/20100624/DA25925LOGO ) ...
Cached Biology Technology:Athera Signs Distribution Agreement in Scandinavia 2Athera Signs Distribution Agreement in Scandinavia 3Athera Signs Distribution Agreement in Scandinavia 4Athera Signs Distribution Agreement in Scandinavia 5Athera Signs Distribution Agreement in Scandinavia 6Athera Signs Distribution Agreement in Scandinavia 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9SciQuest Makes the Inc. 500|5000 List of Fastest-Growing Companies for Fourth Consecutive Year 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... have sexes, just so-called mating types. A new study ... there are great similarities between the parts of DNA that ... of DNA that determine mating types in certain fungi. ... of the evolutionary development of sex chromosomes. In the ...
... National Lung Cancer Partnership, in partnership with the ... their third annual research grant competition. The ... in basic lung cancer biology, risk assessment, prevention, detection, ... Genentech and our very generous donors, were able to ...
... leading causes of blindnessage-related macular degeneration and diabetic retinopathycan ... a protein found in blood vessel cells, researchers at ... other institutions have announced in a new study. ... when the protein, Robo4, was activated in mice models ...
Cached Biology News:Fungi can tell us about the origin of sex chromosomes 2National Lung Cancer Partnership and LUNGevity Foundation 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: